Malaria - Goals

Sanofi-aventis adheres to the Millennium Goals developed by the United Nations, in particular:

Eradicate extreme poverty and hunger (Millennium Goal 1)
By 2015, halt and begin to reverse the incidence of malaria and other major diseases (Millennium Goal 6, target 8)
Provide access to affordable essential drugs in developing countries (Millennium Goal 8, target 17)
Improve maternal health (Millennium Goal 5)

Areas for Progress, Specific Goals and Indicators
Areas for Progress	Specific Goals	Indicators
Research and develop new antimalarial drugs to anticipate the development of resistance to current treatments Study vaccine approaches	Conduct research and develop partnerships with outside organizations that work in the field of malaria treatment or prevention	The Group has set up a Research and Development program on infectious diseases, including malaria
Improve existing medicines so they are better adapted to patients' needs	Bring ASAQ to market in Africa, making it available at cost for public markets Bring to market a pediatric emergency kit for the intra-rectal administration of quinine Open three new clinical investigation centers in sub-Saharan Africa	ASAQ is marketed or about to be marketed in most sub-Saharan African countries (already marketed in 19 countries in late 2007) Sales on the private market are tracked using international databases
Increase IEC initiatives (Information, Education and Communication)	Improve care provided by healthcare professionals for the treatment of malaria Improve local populations' ability to protect themselves against the risk of contracting malaria	Initiatives designed for medical personnel Initiatives for local populations and communities
Continue a differential pricing policy to ensure all patients will have access to our antimalarial medicines	Increase the number of patients who have access to sanofi aventis antimalarial drugs through public and private markets	Monitor sales volumes on private and public markets

Top of page